anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
EyePoint Pharmaceuticals · consulting-deck

Eyepoint Goldman Sachs June 10 2025

29 pages · 0 arc beats · 0 loops

Consulting-Deck Download JSON
Unlock

Eyepoint Goldman Sachs June 10 2025

EyePoint Pharmaceuticals
arc beats above · slides in the middle · loops below · scroll → 0 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 1
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

1
coverage by narrative range · generated from this deck JSON
Narrative range 29 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Whole deck 29 slides 100% 29/29 slides 100% 29/29 slides · 170 hits
— 0/29 slides
27.6% 8/29 slides · 9 hits 24.1% 7/29 slides
— 0/29 slides
— 0/29 slides

Slide inventory

29
every slide · same image gating as the playbook
01
Slide 1
front_matter
Open slide detail
02
other
Open slide detail
03
The slide uses a list of callout boxes to highlight key company milestones and financial status.summarize
Open slide detail
04
The slide uses a timeline-based visualization to show the status of drug development programs.present_solution
Open slide detail
05
frame_problem
Open slide detail
06
The slide uses a horizontal process-like flow to present key metrics.size_opportunity
Open slide detail
07
The slide emphasizes the bioerodible nature and small size of the insert compared to legacy technology.present_solution
Open slide detail
08
The slide explains the mechanism of action (Vorolanib) and the delivery technology (Durasert E) for the product DURAVYU.present_solution
Open slide detail
09
The slide uses a table-like structure to map clinical trials (DAVIO, DAVIO 2, PAVIA, VERONA) to patient counts and key outcomes.illustrate_case
Open slide detail
10
front_matter
Open slide detail
11
The slide uses a four-column layout to present strategic advantages.present_solution
Open slide detail
12
quantify_impact
Open slide detail
13
Includes a callout box regarding LUGANO enrollment status.present_framework
Open slide detail
14
The slide uses a timeline framework to track trial progress from Jan 2025 to mid-2026.summarize
Open slide detail
15
Includes company logo and copyright information.front_matter
Open slide detail
16
The slide uses a timeline-based visual to contrast injection frequency across five different pharmaceutical products.compare_options
Open slide detail
17
The slide uses a timeline-based study design framework.illustrate_case
Open slide detail
18
The slide uses a split-layout with a summary/thesis on the left and specific trial results on the right.illustrate_case
Open slide detail
19
The chart compares DURAVYU 2.7mg, 1.3mg, and aflibercept 2mg. A red box highlights the early improvement at Week 4.illustrate_case
Open slide detail
20
The outlier patient missed multiple visits, leading to significant vision loss at week 24.quantify_impact
Open slide detail
21
The chart compares DURAVYU 2.7mg, DURAVYU 1.3mg, and Aflibercept 2mg. The final values at Week 24 are highlighted in a box.quantify_impact
Open slide detail
22
Includes company logo and copyright/disclaimer footer.front_matter
Open slide detail
23
Supplement-free is defined as patients who did not receive a supplement at any point during the study.quantify_impact
Open slide detail
24
The slide uses a timeline to show the transition from standard-of-care anti-VEGF injections to the DURAVYU treatment.illustrate_case
Open slide detail
25
The slide uses a timeline to show prior SOC injections followed by the DURAVYU treatment and subsequent follow-up.illustrate_case
Open slide detail
26
summarize
Open slide detail
27
establish_context
Open slide detail
28
summarize
Open slide detail
29
front_matter
Open slide detail